Category: Business

SYDNEY, AUSTRALIA / ACCESS Newswire / June 2, 2025 / Dateline Resources Limited (ASX:DTR)(OTC:DTREF) announces an update on its 100%-owned Colosseum Gold and Rare Earth Element (REE) Project in California, detailing recent exploration findings and planned activities for 2025. Recent geological mapping and data analysis indicate the potential for the project’s known resources to be significantly larger, based on evidence of a potentially broader mineralized system.

The Colosseum Project has a JORC-2012 compliant Mineral Resource of 27.1 million tons at 1.26 g/t gold, totaling 1.1 million ounces, with 455,000 ounces classified as Measured, 281,000 ounces as Indicated, and 364,000 ounces as Inferred. An economic assessment announced on May 23, 2025, reported an NPV of US$550 million and an IRR of 61% at a gold price of US$2,900/oz.

Recent re-examination of 2023 gravity survey data, cross referenced with new geochemical results, shows that gravity low anomalies align with the historically mined North and South breccia pipes and newly identified felsite outcrops located 200-900 meters west and southwest of the previously mined pits. This correlation suggests the presence of additional breccia pipes, which could host further gold mineralization. The data supports an interpretation of the Colosseum deposit as a larger breccia pipe complex, with the mined pipes potentially representing only the upper, eroded portions of a more extensive system.

Figure 1: Cross-section A-A′ (looking approximately north) showing the drilled Colosseum breccia pipe (blue volume) cantered within a pronounced gravity low (light blue colour) and recently sampled felsite dykes (red arrows) to the west also sit in gravity lows.

To further define this potential, Dateline will commence a comprehensive exploration program in June 2025. A four-week soil geochemical survey will collect samples across the project area on systematic grids to identify gold, REE, and pathfinder element anomalies. Concurrently, a magneto telluric (MT) geophysical survey will begin in late June to map subsurface structures and potential REE-bearing carbonatite bodies. These surveys will provide complementary datasets to refine drill targets. Dateline’s technical team will integrate gravity, geochemical, and MT data to prioritize areas where these indicators converge, enhancing the likelihood of identifying potential mineralized zones.

Figure 2: Plan view map showing gravity data overlaid with proposed soil sampling locations (purple dots at 60 m spacing). The mined North and South breccia pipes lie within a central gravity low (blue), while newly sampled felsite outcrops on the western margin also coincide with a gravity low. Two circular gravity lows to the east of the pits represent untested potential breccia pipe targets. The soil sampling program is designed to geochemically test all these features to support vectoring for both gold and REE mineralisation

A dedicated REE drilling program is being finalized to test high-priority targets, including depth extensions of REE-bearing fenite/trachyte dykes and coincident gravity-MT anomalies. Drilling will also probe for extensions of the known gold-bearing breccia pipes and newly indicated targets. The program, supported by REE geologists Dr. Tony Mariano and Tony Mariano Jr., aims to confirm the presence and scale of additional gold and REE mineralization.

The Colosseum Project is located in the Walker Lane Trend, less than 10km from the Mountain Rare Earth mine, positioning it favorably for REE exploration. The combination of existing resources, new geological insights, and planned exploration supports the potential for significant resource growth.

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR) is an Australian publicly listed company focused on high-value mining and exploration in North America. The Colosseum REE and Gold Project, located in California’s Walker Lane Trend, is a flagship asset with emerging REE potential and proven gold resources.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or future performance and include, but are not limited to, statements regarding the potential of the Colosseum Project, the expected benefits of the OTCQB listing, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on the company’s current expectations, estimates, and projections, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to: fluctuations in the prices of gold and rare earth elements; changes in regulatory requirements or permitting processes; geological or technical challenges in exploration and development; market conditions affecting the company’s ability to raise capital; environmental or social factors impacting operations; risks associated with the OTCQB listing process or trading on a new market; environmental and permitting risks associated with operating in a national preserve; uncertainty regarding the delineation of a mineable rare earth elements resource; risks related to the company’s ability to secure necessary funding for project development; and potential changes in government policies or priorities affecting the critical minerals sector. The company cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Competent Person Statement

The exploration data has been reviewed by Mr. Greg Hall, a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM) and Non-Executive Director of Dateline. Mr. Hall, with extensive experience in IRGS-style mineralization, qualifies as a Competent Person under the JORC Code and consents to the inclusion of this information.

Contact Information

For further details, please contact:

• Stephen Baghdadi, Managing Director, +61 2 9375 2353, www.datelineresources.com.au

• Andrew Rowell, White Noise Communications, +61 400 466 226, andrew@whitenoisecomms.com

Follow Dateline on X: @Dateline_DTR

This announcement is authorized for release by the Dateline Resources Limited Board of Directors.

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

IRS Debt Doesn’t Just Lead to Penalties – It Can Derail Major Life Goals, Warns Clear Start Tax

IRVINE, CA / ACCESS Newswire / June 2, 2025 / For many Americans, back taxes may seem like a personal issue, but the consequences extend far beyond IRS notices. According to Clear Start Tax, a nationally recognized tax resolution firm, unpaid tax debt can severely damage your credit, block financial opportunities, and create lasting setbacks that impact everything from buying a home to securing a loan or job.

“People think of the IRS as separate from their financial reputation,” said the Head of Client Solutions at Clear Start Tax. “But a tax lien or collection activity can hit your credit and your long-term goals harder than you expect.”

What Ignoring Back Taxes Could Really Cost You

Failing to address back taxes doesn’t just leave you with a growing balance – it opens the door to enforcement actions that can affect your income, assets, and long-term financial health. As Clear Start Tax explains, IRS collection efforts often begin quietly but can escalate quickly and aggressively if left unresolved. Some of the most serious consequences include:

• Tax liens can be filed against your property and reported to credit bureaus, reducing credit scores and limiting your ability to borrow.

• Bank levies can drain your accounts with little warning, leaving you without access to needed funds.

• Wage garnishments can reduce your take-home pay and create a cycle of financial instability.

• Interest and penalties compound daily, quickly increasing what you owe.

Clear Start Tax notes that these consequences don’t just harm your current finances – they also delay or destroy future plans, including mortgage approvals, car loans, small business funding, and even job applications with financial background checks.

Credit Damage Can Linger Long After the Tax Is Paid

Even after a tax debt is resolved, the financial damage can linger. Public records like tax liens (when reported) and collection actions can remain on credit reports for years. And if a taxpayer entered into a payment plan late-or only after enforcement began-that history may still reflect negatively in the eyes of lenders or employers.

“Back taxes aren’t just a balance to pay-they can become a barrier to progress,” added the Head of Client Solutions at Clear Start Tax. “We’ve worked with clients who couldn’t refinance their homes or qualify for financing because of unresolved tax issues that were years old.”

How Clear Start Tax Helps Clients Protect Their Credit and Rebuild Confidence

Clear Start Tax offers personalized solutions that do more than just address the debt-they help safeguard credit and prevent long-term damage. The firm works with each client to:

• Conduct a full IRS and credit risk review

• Recommend the right IRS program (such as Offer in Compromise, Installment Agreement, or CNC status)

• Prevent or remove liens and stop garnishments

• Ensure timely filings to maintain eligibility for relief

• Provide guidance on staying compliant to rebuild financial health

With the right strategy and early action, most taxpayers can avoid the worst outcomes and take back control of their financial future.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

INDIANAPOLIS, INDIANA / ACCESS Newswire / June 2, 2025 / Arrive AI (NASDAQ:ARAI), an autonomous delivery network anchored by patented AI-powered Arrive Points™, announced today that Laurie Tucker, has joined its Board of Directors. Tucker, a former Senior Vice President of Marketing at FedEx and an experienced board member, brings invaluable logistics and strategic expertise to Arrive AI.

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / June 2, 2025 / CoTec Holdings Corp. (TSXV:CTH) (“CoTec” or the “Company“) today announces that it has received the approval of the TSX Venture Exchange (the “TSXV“) for the conversion component of its convertible loan agreement dated November 25, 2024 (as amended, the “Convertible Loan Agreement“) with Kings Chapel International Limited (“Kings Chapel“), previously disclosed in the Company’s news releases dated November 25, 2024 and February 28, 2025.

The outstanding principal amount under the Convertible Loan Agreement as at May 30, 2025 is $6,351,387 and $664,668 in interest has accrued thereunder.

The outstanding principal amount under the Convertible Loan Agreement will be converted into common shares of the Company (“Common Shares“) (i) at any time at Kings Chapel’s election, at a price of CAD$0.75 per Common Share, and (ii) automatically at a price of CAD$0.75 per Common Share, on the first day on which the volume weighted average trading price of the Common Shares on the principal stock exchange on which the Common Shares are then traded over the immediately preceding 15 trading days is equal to or greater than CAD$1.00. No conversion of the outstanding principal amount will occur to the extent that, after giving effect to the conversion, Kings Chapel, its affiliates and any person with whom Kings Chapel or its affiliates would own more than 49% of the outstanding Common Shares.

Kings Chapel is an existing insider and Control Person (as defined by TSX Venture Exchange (“TSXV“) Rules) of the Company. Julian Treger, a director of the Company and its Chief Executive Officer, is a beneficiary of a family trust associated with Kings Chapel. As a result, the execution of the Convertible Loan Agreement was a related party transaction subject to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI61-101“). The execution of the Convertible Loan Agreement was exempt from the formal valuation requirements of MI 61-101 pursuant to subsection 5.5(b) of MI 61-101 because the Common Shares are listed only on the TSXV and is exempt from the minority shareholder approval requirements of MI 61-101 pursuant to subsection 5.7(1)(a) of MI 61-101 because the fair market value of neither the Convertible Loan Agreement nor the Common Shares issuable pursuant to the conversion of the outstanding principal amount under the Convertible Loan Agreement exceed 25% of the Company’s market capitalization as determined in accordance with MI 61-101.

All securities issuable in connection with the Convertible Loan Agreement will be subject to a statutory hold period of four months plus a day from the date of the Convertible Loan Agreement in accordance with applicable securities legislation in Canada.

About CoTec

CoTec is a publicly traded investment issuer listed on the TSXV and the OTCQB and trades under the symbol CTH and CTHCF respectively. CoTec is a forward-thinking resource extraction company committed to revolutionizing the global metals and minerals industry through innovative, environmentally sustainable technologies and strategic asset acquisitions. With a mission to drive the sector toward a low-carbon future, CoTec employs a dual approach: investing in disruptive mineral extraction technologies that enhance efficiency and sustainability while applying these technologies to undervalued mining assets to unlock their full potential. By focusing on recycling, waste mining and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s strategic model delivers low capital requirements, rapid revenue generation and high barriers to entry, positioning it as a leading mid-tier disruptor in the commodities sector.

For more information, please visit www.cotec.ca.

For further information, please contact:

Braam Jonker – (604) 992-5600

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

HESPERIA, CA / ACCESS Newswire / June 2, 2025 / 5E Advanced Materials, Inc.(NASDAQ:FEAM)(ASX:5EA) (“5E” or the “Company”), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, announced today that Chief Executive Officer Paul Weibel will present at the MicroCap Rodeo Conference on Wednesday, June 4, 2025, in New York City. In addition to the live presentation, management will host one-on-one meetings with investors registered to attend the event.

The presentation will begin at 2:30 p.m. ET on June 4. Investors interested in viewing the webcast can register here. The webcast and associated presentation can also be accessed through the investor section of the Company’s website at: https://investors.5eadvancedmaterials.com/events-presentations.

For more details about the MicroCap Rodeo Conference in New York City, please visit https://www.microcaprodeo.com/.

About 5E Advanced Materials, Inc.

5E Advanced Materials, Inc. (NASDAQ:FEAM)(ASX:5EA) is focused on becoming a vertically integrated global leader and supplier of boron specialty and advanced materials, complemented by lithium co-product production. The Company’s mission is to become a supplier of these critical materials to industries addressing global decarbonization, food and domestic security. Boron and lithium products will target applications in the fields of electric transportation, clean energy infrastructure, such as solar and wind power, fertilizers, and domestic security. The business strategy and objectives are to develop capabilities ranging from upstream extraction and product sales of boric acid, lithium carbonate and potentially other co-products, to downstream boron advanced material processing and development. The business is based on our large domestic boron and lithium resource, which is located in Southern California and designated as Critical Infrastructure by the Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact included in this press release regarding the Company’s business strategy, plans, goals, and objectives, including regarding the anticipated changes to the Company’s board of directors and management and anticipated benefits, are forward-looking statements. When used in this press release, the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “intent,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the extraction of the critical materials we intend to produce and advanced materials production and development. These risks include, but are not limited to: our limited operating history in the borates and lithium industries and no revenue from our proposed extraction operations at our properties; our need for substantial additional financing to execute our business plan and our ability to access capital and the financial markets; our status as an exploration stage company dependent on a single project with no known Regulation S-K 1300 mineral reserves and the inherent uncertainty in estimates of mineral resources; our lack of history in mineral production and the significant risks associated with achieving our business strategies, including our downstream processing ambitions; our incurrence of significant net operating losses to date and plans to incur continued losses for the foreseeable future; risks and uncertainties relating to the development of the Fort Cady project, including our ability to timely and successfully complete our proposed Commercial Scale Boron Facility; our ability to obtain, maintain and renew required governmental permits for our development activities, including satisfying all mandated conditions to any such permits; the implementation of and expected benefits from certain reduced spending measures, and other risks and uncertainties set forth in our filings with the U.S. Securities and Exchange Commission from time to time. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. These risks are not exhaustive and the information in this press release may be subject to additional risks. No representation or warranty (express or implied) is made as to, and no reliance should be place on, any information, including projections, estimates, targets, and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions, or misstatements contained herein. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as to the date of this press release.

For additional information regarding these various factors, you should carefully review the risk factors and other disclosures in the Company’s Form 10-K filed on September 9, 2024 and subsequent filings with the U.S. Securities and Exchange Commission throughout the year, as well as in its filings under the Australian Securities Exchange. Any forward-looking statements are given only as of the date hereof. Except as required by law, 5E expressly disclaims any obligation to update or revise any such forward-looking statements. Additionally, 5E undertakes no obligation to comment on third party analyses or statements regarding 5E’s actual or expected financial or operating results or its securities.

For further information contact:

Joseph Caminiti or Nathan Skown
Alpha IR Group
FEAM@alpha-ir.com
Ph: +1(312) 445-2870

SOURCE: 5E Advanced Materials, Inc.

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / June 2, 2025 / Cerrado Gold Inc. (TSXV:CERT)(OTCQX:CRDOF)(FRA:BAI0) (“Cerrado” or the “Company“) is pleased to announce the appointment of Ed Guimaraes to the position of Executive Vice President, effective June 1, 2025.

Mr. Guimaraes has over 30 years of experience in the mining industry, most recently in an executive advisory capacity and through several board directorships. His career spans a broad range of base and precious metals producers, having supported the development, expansion, and ongoing operations of copper, zinc, lead, gold, and silver mines in Canada, Chile, Peru, Mexico and Argentina. Mr. Guimaraes previously acted as the Chief Financial Officer at Sierra Metals between 2014 and 2023, and he was with Aur Resources between 1995 and 2007, ultimately serving as Executive Vice-President, Finance and Chief Financial Officer, until its acquisition by Teck Resources in 2007 for US$4.1 billion. Prior to 1995, he worked in the Toronto mining group of PricewaterhouseCoopers. Mr. Guimaraes is a Chartered Professional Accountant (CPA, CA), a graduate of the ICD-Rotman Directors Education Program (ICD.D) and holds a Bachelor of Arts in Administrative and Commercial Studies from Western University.

Mark Brennan, Executive Chairman, commented: “On behalf of the Board and Management, I would like to welcome Ed to the team. We had very strong success working together growing Sierra Metals, and his extensive financial and operational experience supporting development and expansion of projects will add significant benefit to the Company as we continue to grow the Minera Don Nicolas gold mine to its full potential and advance the Lagoa Salgada VMS and Mont Sorcier High Purity Iron Ore Projects.”

About Cerrado

Cerrado Gold is a Toronto-based gold production, development, and exploration company. The Company is the 100% owner of the producing Minera Don Nicolás and Las Calandrias mine in Santa Cruz province, Argentina. In Portugal, the Company holds an 80% interest in the highly prospective Lagoa Salgada VMS project through its position in Redcorp – Empreendimentos Mineiros, Lda. In Canada, Cerrado Gold is developing its 100% owned Mont Sorcier Iron project located outside of Chibougamou, Quebec.

In Argentina, Cerrado is maximizing asset value at its Minera Don Nicolas operation through continued operational optimization and is growing production through its operations at the Las Calandrias heap leach project. An extensive campaign of exploration is ongoing to further unlock potential resources in our highly prospective land package in the heart of the Deseado Masiff.

In Portugal, Cerrado is focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. The Lagoa Salgada project is a high-grade polymetallic project, demonstrating a typical mineralization endowment of zinc, copper, lead, tin, silver, and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 7,209-hectare property concession. Located just 80km from Lisbon and surrounded by exceptional infrastructure, Lagoa Salgada offers a low-cost entry to a significant exploration and development opportunity, already showing its mineable scale and cashflow generation potential.

In Canada, Cerrado holds a 100% interest in the Mont Sorcier high purity Iron project, which has the potential to produce a premium iron concentrate over a long mine life at low operating costs and low capital intensity. Furthermore, its high grade and high purity product facilitates the migration of steel producers from blast furnaces to electric arc furnaces, contributing to the decarbonization of the industry and the achievement of sustainable development goals.

For more information about Cerrado please visit our website at: www.cerradogold.com.

Mark Brennan
CEO and Chairman

Mike McAllister
Vice President, Investor Relations
Tel: +1-647-805-5662
mmcallister@cerradogold.com

Disclaimer

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains statements that constitute “forward-looking information” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements contained in this press release include, without limitation, statements regarding the business and operations of Cerrado.

SOURCE: Cerrado Gold Inc.

View the original press release on ACCESS Newswire

mNEXSPIKE becomes Moderna’s third FDA-approved product

CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE® (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease Control and Prevention (CDC).^[1]

“The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from COVID-19,” said Stéphane Bancel, Chief Executive Officer of Moderna. “COVID-19 remains a serious public health threat, with more than 47,000 Americans dying from the virus last year alone. We appreciate the FDA’s timely review and thank the entire Moderna team for their hard work and continued commitment to public health.”

The FDA’s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax®), Moderna’s original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.

In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions. The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA®, the Company’s approved respiratory syncytial virus (RSV) vaccine.

mRNA-1283 is under review with regulators in multiple markets around the world.

About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

mNEXSPIKE®, mRESVIA® and Spikevax®are registered trademarks of Moderna.

INDICATION
mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who have received a COVID-19 vaccine before and are:

• 65 years of age and older, or

• 12 years through 64 years of age at high risk for severe COVID-19.

Vaccination with mNEXSPIKE may not protect all people who receive the vaccine.

IMPORTANT SAFETY INFORMATION

You should not get mNEXSPIKE if you hada severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX (COVID-19 Vaccine, mRNA), or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.

What are the risks of mNEXSPIKE?
There is a very small chance that mNEXSPIKE could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:

• Trouble breathing

• Swelling of your face and throat

• A fast heartbeat

• A rash all over your body

• Dizziness and weakness

Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving the vaccine, particularly during the 2 weeks after receiving a dose of the vaccine:

• Chest pain

• Shortness of breath

• Feelings of having a fast-beating, fluttering, or pounding heart

Side effects that have been reported in clinical trials with mNEXSPIKE include:

• Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.

• General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever

Tell your vaccination provider about all of your medical conditions, including if you:

• have any allergies

• had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

• have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

• have a fever

• have a bleeding disorder or are on a blood thinner

• are immunocompromised or are on a medicine that affects your immune system

• are pregnant or plan to become pregnant

• are breastfeeding

• have received any other COVID-19 vaccine

• have ever fainted in association with an injection

These may not be all the possible side effects of mNEXSPIKE. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

Please click for mNEXSPIKE Full Prescribing Information.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mNEXSPIKE; and the availability of Moderna’s respiratory vaccines for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

View the original press release on ACCESS Newswire

ORLANDO, FL / ACCESS Newswire / May 30, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and FatPipe, Inc. (Nasdaq:FATN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 31, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

• NXL: https://www.redchip.com/assets/access/nxl_access

• FATN: https://www.redchip.com/assets/access/fatn_access

In an exclusive interview, Nexalin CEO Mark White appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin’s solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries – conditions that affect millions but have limited effective treatments – positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030.

In an exclusive interview, Dr. Ragula Bhaskar, CEO of FatPipe, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how the company is transforming enterprise connectivity through its patented, software-defined networking technologies. With a product suite spanning SD-WAN, Secure Access Service Edge (SASE), and Network Monitoring Services (NMS), FatPipe enables over 2,500 customers – including government agencies, financial institutions, and healthcare providers – to unify, secure, and optimize their networks across cloud, hybrid, and on-premise environments. Dr. Bhaskar highlights FatPipe’s robust financial performance, including $17.9 million in revenue and $4.4 million in net income for fiscal 2024, and outlines the company’s growth strategy focused on global expansion, product innovation, and deepening its high-margin, subscription-based revenue model. Positioned at the intersection of three multi-billion-dollar markets and operating as a “Rule of 40” business, FatPipe offers investors a compelling blend of profitability, scalability, and exposure to the accelerating digital infrastructure megatrend.

NXL and FATN are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

About FatPipe, Inc.

FatPipe pioneered the concept of software-defined wide area networking (SD-WAN) and hybrid WANs that eliminate the need for hardware and software or cooperation from ISPs and allows companies and service providers to control multi-link network traffic. FatPipe currently has 12 U.S. patents related to multipath, software-defined networking. FatPipe products are sold by 200+ resellers worldwide. For more information, visit www.fatpipeinc.com. Follow us on X @FatPipe_Inc.

To learn more, visit www.fatpipeinc.com or contact sales321@fatpipeinc.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip’s products and services, please visit:

https://www.redchip.com/corporate/investor_relations

“Discovering Tomorrow’s Blue Chips Today”™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com

SOURCE: RedChip Companies, Inc.

View the original press release on ACCESS Newswire